Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics Alnylam has a deep pipeline of investigational medicines, including six product

2017-09-20

Das Unternehmen Alnylam ist führend bei der Umsetzung der RNA-Interferenz (RNAi) in eine innovative neue Arzneimittelklasse für Patienten mit eingeschränkten oder unzureichenden Behandlungsmöglichkeiten. Unsere Pipeline umfasst RNAi-Entwicklungssubstanzen für vier seltene Therapiebereiche: genetische Krankheiten, Herz- und パイプライン. Alnylam (アルナイラム)は、RNA interference（RNAi）治療薬のリーディングカンパニーとして、RNAiを応用した全く新しい創薬を通じ、限られた治療選択肢しか無い患者さまに新しい治療薬と希望をもたらすことを目指している会社です。. 私たちの開発中のRNAi治療薬のパイプラインは4つの戦略的治療分野 (STArs：Strategic Therapeutic Areas )である遺伝性疾患、心血管 Alnylam wurde im Jahr 2002 gegründet und verfolgt eine kühne Vision: Wir verwandeln wissenschaftliches Potenzial in reale Therapien – mit einer robusten Forschungsplattform und einer umfangreichen Pipeline investigativer Medikamente, darunter bereits drei in der EU und in den USA zugelassene Medikamente, fünf Produktkandidaten in den letzten Untersuchungsphasen und zahlreiche Prüfungsmedikamente in der Entwicklung. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Proceed to Site You are now leaving Alnylam.com Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “ Alnylam P 5 x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech Alnylam grundades 2002 och levererar en djärv vision om att förvandla vetenskapliga möjligheter till verklighet, med en robust forskningsplattform och flera läkemedel under utveckling i pipeline och två produkter som har godkänts i USA och Europeiska unionen.

Alnylam is leading the translation of RNAi (RNA interference) into a whole new class of innovative medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic OUR PIPELINE. Alnylam is leading the translation of RNAi (RNA interference) into an innovative new class of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall into 4 Strategic Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam has been executing on its " Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options.

At Alnylam, transformational, world-leading science is at the core of who we are, and trust, honesty, and integrity are deeply important to how we operate. As an extension of our company culture, Alnylam believes that timely disclosure of clinical study information is important to help advance medical research, inform patients and physicians, and

Blackstone will 3 days ago Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is Cambridge, Massachusetts 101,657 followers. Alnylam is the leading RNAi therapeutics company.

Our Pipeline Clinical Trials Medical Professionals. Medical Professionals Genetic Testing & Counseling Early Access Program September 10, 2020 Brendan Martin on the Pharmaphorum Podcast Alnylam’s Brendan Martin, Head of Europe, Middle East,

31,41 IPL:CT Pembina Pipeline. 282 459. 98,14 PPL:CT Alnylam Pharmaceuticals. 36 884. 39,77 ALNY:UW.

763. 0,02. The Williams Companies Genmab. 54. 92. 0,00. Alnylam Pharmaceuticals Inc. 97.
Skriptfel dator

Pembina Pipeline Corp.

40,51 Transcanada Pipelines. Energi. 39 956.
Den lokala styrelsen

Jan 13, 2014 on Rare Genetic Diseases. - Genzyme to Obtain Significant Global Rights to Alnylam's Pipeline -. - Alnylam Retains Most Product Rights in North

Patisiran är en av flera värdefulla kandidater i Alnylams pipeline för tillfället och längst längs utvecklingenstidslinjen. Food and Drug Administration förväntas som enligt förvaltarna också utvecklades väl, till följd av positiva pipeline-utvecklingar. Sämre kursutveckling hade innehaven Alnylam och Alnylam tillkännagav nyligen att det amerikanska FDA har beviljat vutrisiran 6 RNAi-behandlingar i företaget 00 1 00 1 0 # 39; s pipeline som är i sen klinisk Aegerion Pharmaceuticals; Aegion; Aerie Pharmaceuticals; Albany International; Alexandria Real Estate Equities; Alnylam Pharmaceuticals; American Capital Alnylam is the world's leading RNA interference (RNAi) company. with three approved medicines and a robust pipeline of investigational medicines focused in Alnylam Logo 4.4. Alnylam · Medical Science Liaison, Nordics MSL Pipeline Oncology - NL, BE & Scandinavia. Stockholm. 30d.